Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
Titel:
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
Auteur:
Damodaran, S. O’Sullivan, C.C. Elkhanany, A. Anderson, I.C. Barve, M. Blau, S. Cherian, M.A. Peguero, J.A. Goetz, M.P. Plourde, P.V. Portman, D.J. Moore, H.C.F.